author-photo

C. Valsuani

22

Papers

253

Citations

Citation Trend

Filter By

Papers (13) Sort By

Journal Conference Others

R18Cancer as family disease

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group

2017 BMC Cancer
Show All
- Source
- Cite
- Save
Citations (17)
Additional file 1: of TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group

2017
Show All
- Source
- Cite
- Save
Citations (0)
Dystroglycan expression correlates with tumor grade and with outcome in renal cell carcinoma patients

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
R56X-Rays absorption evaluation in cancer patients submitted to cosmeceutical prophylaxis with smoothing emulsion and sun protecion factor cream during radiotherapy

2015 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Preliminary results of the phase II randomized Macbeth trial by GONO group.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
O-0007SUBGROUP ANALYSES IN RAS MUTANT, BRAF MUTANT AND “ALL WT” METASTATIC COLORECTAL CANCER PATIENTS TREATED WITH FOLFOXIRI PLUS BEVACIZUMAB (BEV) OR FOLFIRI PLUS BEV IN THE TRIBE STUDY

2014 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (3)
O-0027BEVACIZUMAB BEYOND PROGRESSION IN METASTATIC COLORECTAL CANCER PATIENTS RECEIVING A FIRST-LINE TREATMENT CONTAINING BEVACIZUMAB: UPDATE OF BEBYP TRIAL BY GONO

2013 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial.

2013 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (33)
Second-line chemotherapy (CT) with or without bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts) who progressed to a first-line treatment containing BV: Updated results of the phase III "BEBYP" trial by the Gruppo Oncologico Nord Ovest (GONO).

2013 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (18)